GV20 Therapeutics Collaborates with Merck to Evaluate GV20-0251 + KEYTRUDA in Patients with Advanced Solid Tumors
Shots:
- GV20 Therapeutics enters into a clinical collaboration and supply agreement with Merck to investigate GV20-0251 + KEYTRUDA under its ongoing P-I study
- GV20 is currently enrolling participants in P-I study, evaluating safety, tolerability, PK, PD, and preliminary anti-tumor activity of GV20-0251 as a monotx. and in combination with KEYTRUDA in advanced solid tumors patients, not eligible for SoC
- GV20-0251, Fc-attenuated IgG1 monoclonal antibody targeting innate immune checkpoint IGSF8; has been evaluated with Merck's Keytruda, an anti-PD-1 therapy
Ref: GV20 Therapeutics | Image: GV20 Therapeutics
Related News:- Merck Commences P-III Study of MK-1084 Plus Keytruda as a Treatment of Metastatic Non-Small Cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
